Replies to post #160358 on Biotech Values

[genisi]

Sphingosine 1- Phosphate (S1P) receptor agonists in MS

What are the first gen S1P1 drugs

Novartis’s Gilenya is the 1st gen S1P1,3-5-R pan-agonist.

who are the other competitors in the next gen space besides RCPT?

Novartis has a next gen S1PR - Siponimod (BAF312) in phase III for SPMS: http://clinicaltrials.gov/ct2/show/NCT01665144?term=Siponimod&rank=1
Merck/Ono's ONO-4641 in phase II for RRMS: http://clinicaltrials.gov/ct2/show/NCT01226745?term=ONO-4641&rank=1
Actelion's Ponesimod in phase II for RRMS: http://clinicaltrials.gov/ct2/show/NCT01093326?term=Ponesimod&rank=1

how hot of an MS target S1P1 is right now

The name of the game is more selective S1PR agonists with improved safety profile compared to the 1st gen - Gilenya and I think so far they are all hitting bumps and the S1P system is not sufficiently understood.